Luis Paz-Ares is currently Chairman of the Medical Oncology Department at the Hospital Doce de Octubre, Head of the Lung Cancer Unit at the CNIO (National Oncology Research Center), Associate Professor at the Universidad Complutense, and President of Oncosur Foundation, all in Madrid, Spain.
He graduated with a degree in Medicine from the Universidad Autonoma de Madrid, in 1986, and completed a PhD in 1993 at the same university. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, Glasgow, Scotland (1993–1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995. Luis Paz-Ares also completed a Master’s degree in Clinical Unit Management at the UNED-Fundación Universidad Empresa (2002–2003).
Prior to his current position, he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), and Vice-Director of the Seville Biomedicine Research Institute (IBIS) Head of the Pharmacology Unit and responsible for early clinical studies of thoracic and genitourinary tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).
Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 240 papers in peer reviewed journals, as well as many book chapters, including New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology and many others.He is an active member of various scientific societies (including ASCO, ESMO,ELCC, IASLC and other) and collaborative groups (European Organisation for Research and Treatment of Cancer [EORTC], the Spanish Lung Cancer Group and the International Germ Cell Cancer Collaborative Group). At the beginning of 2017 he was awarded for his research work with the Lilly Foundation Award for Biomedical Research (Clinical) and with The Ramiro Carregal Oncology Award. Since the beginning of 2019 he is Vicepresident of the Spanish Association of Cancer Research (ASEICA)
Date of preparation: January 2021